The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 + T Cell Decline and High Viral Load during Acute Infection
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals is needed to guide vaccine design and immunization strategies. Here we used a large panel of 44 HIV-1 envelope variants (subtypes A, B, and C) to evaluate the presence of broadly neutralizing antibodies in serum samples obtained 3 years after seroconversion from 40 women enrolled in the CAPRISA 002 acute infection cohort. Seven of 40 participants had serum antibodies that neutralized more than 40% of viruses tested and were considered to have neutralization breadth. Among the samples with breadth, CAP257 serum neutralized 82% (36/44 variants) of the panel, while CAP256 serum neutralized 77% (33/43 variants) of the panel. Analysis of longitudinal samples showed that breadth developed gradually starting from year 2, with the number of viruses neutralized as well as the antibody titer increasing over time. Interestingly, neutralization breadth peaked at 4 years postinfection, with no increase thereafter. The extent of cross-neutralizing activity correlated with CD4 + T cell decline, viral load, and CD4 + T cell count at 6 months postinfection but not at later time points, suggesting that early events set the stage for the development of breadth. However, in a multivariate analysis, CD4 decline was the major driver of this association, as viral load was not an independent predictor of breadth. Mapping of the epitopes targeted by cross-neutralizing antibodies revealed that in one individual these antibodies recognized the membrane-proximal external region (MPER), while in two other individuals, cross-neutralizing activity was adsorbed by monomeric gp120 and targeted epitopes that involved the N-linked glycan at position 332 in the C3 region. Serum antibodies from the other four participants targeted quaternary epitopes, at least 2 of which were PG9/16-like and depended on the N160 and/or L165 residue in the V2 region. These data indicate that fewer than 20% of HIV-1 subtype C-infected individuals develop antibodies with cross-neutralizing activity after 3 years of infection and that these antibodies target different regions of the HIV-1 envelope, including as yet uncharacterized epitopes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00003 · Cited by 2,067
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Richman, D. D., Wrin, T., Little, S. J., & Petropoulos, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630530100 · Cited by 1,200
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., et al. (2000) · Nature Medicine · doi:10.1038/72309 · Cited by 849
Current Protocols in Immunology
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142735 · Cited by 785
Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
B cells in HIV infection and disease
Moir, S., & Fauci, A. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2524 · Cited by 702
Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01708-08 · Cited by 631
Self-citationEvaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02036-08 · Cited by 528
Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J., Burton, D. R., et al. (2003) · Nature Medicine · doi:10.1038/nm833 · Cited by 460
Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis
Fraser, C., Hollingsworth, T. D., Chapman, R., de Wolf, F., & Hanage, W. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708559104 · Cited by 438
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
Self-citationCorti, D., Langedijk, J. P. M., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008805 · Cited by 426
Abrahams, M.-R., Anderson, J. A., Giorgi, E. E., Seoighe, C., Mlisana, K., Ping, L.-H., Athreya, G. S., Treurnicht, F. K., Keele, B. F., Wood, N., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02132-08 · Cited by 381
Self-citationWalker, L. M., Simek, M. D., Priddy, F., Gach, J. S., Wagner, D., Zwick, M. B., Phogat, S. K., Poignard, P., & Burton, D. R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001028 · Cited by 370
Li, M., Salazar-Gonzalez, J. F., Derdeyn, C. A., Morris, L., Williamson, C., Robinson, J. E., Decker, J. M., Li, Y., Salazar, M. G., Polonis, V. R., et al. (2006) · Journal of Virology · doi:10.1128/jvi.01730-06 · Cited by 359
Self-citationDoria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W., Migueles, S. A., Wrammert, J., Ahmed, R., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01583-08 · Cited by 318
Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G., & Stamatatos, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001251 · Cited by 315
De Milito, A., Nilsson, A., Titanji, K., Thorstensson, R., Reizenstein, E., Narita, M., Grutzmeier, S., Sönnerborg, A., & Chiodi, F. (2004) · Blood · doi:10.1182/blood-2003-07-2375 · Cited by 311
Antibody vs. HIV in a clash of evolutionary titans
Burton, D. R., Stanfield, R. L., & Wilson, I. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505126102 · Cited by 299
Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection
Gray, E. S., Moore, P. L., Choge, I. A., Decker, J. M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K., Shaw, G. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00239-07 · Cited by 299
Self-citationRosa, D., Saletti, G., De Gregorio, E., Zorat, F., Comar, C., D'Oro, U., Nuti, S., Houghton, M., Barnaba, V., Pozzato, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509402102 · Cited by 278
Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.-Y., Longo, N. S., & Dimitrov, D. S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.029 · Cited by 260
Li, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A., Shaw, G. M., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01992-08 · Cited by 259
Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections
Hunziker, L., Recher, M., Macpherson, A. J., Ciurea, A., Freigang, S., Hengartner, H., & Zinkernagel, R. M. (2003) · Nature Immunology · doi:10.1038/ni911 · Cited by 233
Moore, P. L., Ranchobe, N., Lambson, B. E., Gray, E. S., Cave, E., Abrahams, M.-R., Bandawe, G., Mlisana, K., Abdool Karim, S. S., Williamson, C., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000598 · Cited by 233
Self-citationPancera, M., McLellan, J. S., Wu, X., Zhu, J., Changela, A., Schmidt, S. D., Yang, Y., Zhou, T., Phogat, S., Mascola, J. R., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00966-10 · Cited by 224
Goujard, C., Bonarek, M., Meyer, L., Bonnet, F., Chaix, M.-L., Deveau, C., Sinet, M., Galimand, J., Delfraissy, J.-F., Venet, A., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/500213 · Cited by 216
van Loggerenberg, F., Mlisana, K., Williamson, C., Auld, S. C., Morris, L., Gray, C. M., Abdool Karim, Q., Grobler, A., Barnabas, N., Iriogbe, I., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001954 · Cited by 206
Self-citationMoore, P. L., Gray, E. S., Choge, I., Ranchobe, N., Mlisana, K. P., Karim, S. S. A., Williamson, C. E., & Morris, L. (2007) · Journal of Virology · doi:10.1128/jvi.02187-07 · Cited by 187
Self-citationRong, R., Li, B., Lynch, R. M., Haaland, R. E., Murphy, M. K., Mulenga, J., Allen, S. A., Pinter, A., Shaw, G. M., Hunter, E., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000594 · Cited by 184
Gray, E. S., Taylor, N., Wycuff, D., Moore, P. L., Tomaras, G. D., Wibmer, C. K., Puren, A., DeCamp, A., Gilbert, P. B., Wood, B., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00758-09 · Cited by 183
Self-citationMoore, P. L., Gray, E. S., Sheward, D., Madiga, M., Ranchobe, N., Lai, Z., Honnen, W. J., Nonyane, M., Tumba, N., Hermanus, T., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02658-10 · Cited by 159
Self-citationDeliberate removal of T cell help improves virus-neutralizing antibody production
Recher, M., Lang, K. S., Hunziker, L., Freigang, S., Eschli, B., Harris, N. L., Navarini, A. A., Senn, B. M., Fink, K., Lötscher, M., et al. (2004) · Nature Immunology · doi:10.1038/ni1102 · Cited by 116
Peng, B., Wang, L. R., Román, R. G., Davis‐Warren, A., Montefiori, D. C., Kalyanaraman, V. S., Venzon, D. J., Zhao, J., Kan, E., Rowell, T. J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10200-10209.2005 · Cited by 107
Ancestral and consensus envelope immunogens for HIV-1 subtype C
Kothe, D. L., Li, Y., Decker, J. M., Bibollet‐Ruche, F., Zammit, K. P., Salazar, M. G., Chen, Y., Weng, Z., Weaver, E. A., Gao, F., et al. (2006) · Virology · doi:10.1016/j.virol.2006.05.011 · Cited by 96
van Gils, M. J., Bunnik, E. M., Burger, J. A., Jacob, Y., Schweighardt, B., Wrin, T., & Schuitemaker, H. (2010) · Journal of Virology · doi:10.1128/jvi.02622-09 · Cited by 90
Blish, C. A., Nedellec, R., Mandaliya, K. N., et al. (2007) · AIDS · doi:10.1097/qad.0b013e32805e8727 · Cited by 74
Lynch, R. M., Rong, R., Boliar, S., Sethi, A., Li, B., Mulenga, J., Allen, S. A., Robinson, J. E., Gnanakaran, S., & Derdeyn, C. A. (2010) · Journal of Virology · doi:10.1128/jvi.02006-10 · Cited by 67
Pietzsch, J., Scheid, J. F., Mouquet, H., Klein, F., Seaman, M. S., Janković, M., Corti, D., Lanzavecchia, A., & Nussenzweig, M. C. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101176 · Cited by 67
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
Prabakaran, P., Zhu, Z., Xiao, X., Biragyn, A., Dimitrov, A. S., Broder, C. C., & Dimitrov, D. S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902763755 · Cited by 52
Specificities of broadly neutralizing anti-HIV-1 sera
Binley, J. Μ. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32832e06fe · Cited by 30
van Gils, M. J., Edo-Matas, D., Schweighardt, B., Wrin, T., & Schuitemaker, H. (2009) · Journal of General Virology · doi:10.1099/vir.0.015693-0 · Cited by 18
Lang, K. S., Hegazy, A. N., Lang, P. A., Eschli, B., Löhning, M., Hengartner, H., Zinkernagel, R. M., & Recher, M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001162 · Cited by 16
Cited by
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationA Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011) · Science · doi:10.1126/science.1213256 · Cited by 694
Metadata
- Authors
- Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., Abdool Karim, S. S., Morris, L., & and the CAPRISA002 Study Team
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2011-05-15
- Volume
- 85
- Issue
- 10
- Pages
- 4828-4840
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2152440860
- Cited by
- 466
- References
- 53
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.